IMMP vs MLGO Comparison

Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.

MicroAlgo Inc is engaged in the development and application of bespoke central processing algorithms and provides solutions by integrating these algorithms with software or hardware, or both, to streamline digital services. Its services include algorithm optimization, accelerating computing power without hardware upgrades, lightweight data processing, and data intelligence services. Its technology and solutions are mainly in internet multimedia video advertising, where it provides advertising distribution solutions, software services, comprehensive solutions for enterprise customers, and intelligent chips solutions. It derives revenue from central processing algorithm services for internet advertisement and intelligent chips and services, with maximum revenue generated from Mainland PRC.